Kissei Pharmaceutical Partners With Reborna Biosciences for Drug Discovery in Genetic Rare Diseases
Kissei Pharmaceutical (TYO:4547) and Reborna Biosciences have signed a research collaboration agreement for drug discovery in genetic rare diseases, according to a Tokyo Stock Exchange filing on Monday.
The collaboration will use Reborna's RNA-targeting small molecule drug discovery technology.
Kissei will provide upfront payments, research expenses, milestone payments, and royalties, and retain global development and commercialization rights for successful compounds.
Price (JPY): $3560.00, Change: $+20, Percent Change: +0.56%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。